Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890735111> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2890735111 endingPage "iii263" @default.
- W2890735111 startingPage "iii263" @default.
- W2890735111 abstract "Tumor Treating Fields (TTFields) are an established modality for glioblastoma (GBM) treatment administered through the portable Optune system. The efficacy of Optune in newly diagnosed GBM was previously demonstrated in the EF-14 phase 3 trial (n=695). Optune plus temozolomide significantly improved survival in all patient subgroups compared to temozolomide alone, which included those patients ≥ 65 years of age (median OS: 17.1 vs 13.7 months). Here, we report post-marketing surveillance data from elderly patients treated with Optune. A review of adverse events in patients≥65 years of age. Post-market surveillance data were analyzed based on the MedDRA body system (system organ class) preferred terms. A total of 8025 patients were treated with Optune (newly diagnosed glioblastoma 46.1%, recurrent glioblastoma 46.2%, other 7.7%). Of those 2574 patients (32.1%) were ≥ 65 years of age at the time of Optune treatment. 46% of these elderly patients reported ≥ 1 adverse event. Skin reaction was the most prevalent adverse event and occurred in 28% of patients. Similarly, 47% of patients ≥ 18 and <65 years of age (N=5421) experienced at least 1 adverse event and 27% developed skin reaction. The remaining adverse events profile was fairly equally distributed between both age groups. This retrospective analysis demonstrates that Optune is used in patients 65 years of age or older. The adverse event profile in this group of elderly patients is comparable to patients younger than 65 years. The most common adverse event registered was skin reaction, which was also found in the phase 3 EF-11 trial for recurrent GBM and in the EF-14 trial for newly diagnosed GBM patients. In summary, these results underline the safety profile of Optune." @default.
- W2890735111 created "2018-09-27" @default.
- W2890735111 creator A5001167896 @default.
- W2890735111 creator A5031780975 @default.
- W2890735111 creator A5059909608 @default.
- W2890735111 date "2018-09-01" @default.
- W2890735111 modified "2023-10-06" @default.
- W2890735111 title "P01.136 Safety and adverse event profile of tumor treating fields in elderly patients - a post-market surveillance analysis" @default.
- W2890735111 doi "https://doi.org/10.1093/neuonc/noy139.178" @default.
- W2890735111 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6144638" @default.
- W2890735111 hasPublicationYear "2018" @default.
- W2890735111 type Work @default.
- W2890735111 sameAs 2890735111 @default.
- W2890735111 citedByCount "0" @default.
- W2890735111 crossrefType "journal-article" @default.
- W2890735111 hasAuthorship W2890735111A5001167896 @default.
- W2890735111 hasAuthorship W2890735111A5031780975 @default.
- W2890735111 hasAuthorship W2890735111A5059909608 @default.
- W2890735111 hasBestOaLocation W28907351111 @default.
- W2890735111 hasConcept C126322002 @default.
- W2890735111 hasConcept C141071460 @default.
- W2890735111 hasConcept C197636746 @default.
- W2890735111 hasConcept C197934379 @default.
- W2890735111 hasConcept C199475168 @default.
- W2890735111 hasConcept C2776194525 @default.
- W2890735111 hasConcept C2777105317 @default.
- W2890735111 hasConcept C2777389519 @default.
- W2890735111 hasConcept C2777793932 @default.
- W2890735111 hasConcept C3018359032 @default.
- W2890735111 hasConcept C502942594 @default.
- W2890735111 hasConcept C509974204 @default.
- W2890735111 hasConcept C57658597 @default.
- W2890735111 hasConcept C71924100 @default.
- W2890735111 hasConceptScore W2890735111C126322002 @default.
- W2890735111 hasConceptScore W2890735111C141071460 @default.
- W2890735111 hasConceptScore W2890735111C197636746 @default.
- W2890735111 hasConceptScore W2890735111C197934379 @default.
- W2890735111 hasConceptScore W2890735111C199475168 @default.
- W2890735111 hasConceptScore W2890735111C2776194525 @default.
- W2890735111 hasConceptScore W2890735111C2777105317 @default.
- W2890735111 hasConceptScore W2890735111C2777389519 @default.
- W2890735111 hasConceptScore W2890735111C2777793932 @default.
- W2890735111 hasConceptScore W2890735111C3018359032 @default.
- W2890735111 hasConceptScore W2890735111C502942594 @default.
- W2890735111 hasConceptScore W2890735111C509974204 @default.
- W2890735111 hasConceptScore W2890735111C57658597 @default.
- W2890735111 hasConceptScore W2890735111C71924100 @default.
- W2890735111 hasIssue "suppl_3" @default.
- W2890735111 hasLocation W28907351111 @default.
- W2890735111 hasLocation W28907351112 @default.
- W2890735111 hasOpenAccess W2890735111 @default.
- W2890735111 hasPrimaryLocation W28907351111 @default.
- W2890735111 hasRelatedWork W2022150136 @default.
- W2890735111 hasRelatedWork W2398216409 @default.
- W2890735111 hasRelatedWork W2555057678 @default.
- W2890735111 hasRelatedWork W2984657441 @default.
- W2890735111 hasRelatedWork W2995642698 @default.
- W2890735111 hasRelatedWork W3012061428 @default.
- W2890735111 hasRelatedWork W3020019187 @default.
- W2890735111 hasRelatedWork W3179512020 @default.
- W2890735111 hasRelatedWork W3210787730 @default.
- W2890735111 hasRelatedWork W4315649764 @default.
- W2890735111 hasVolume "20" @default.
- W2890735111 isParatext "false" @default.
- W2890735111 isRetracted "false" @default.
- W2890735111 magId "2890735111" @default.
- W2890735111 workType "article" @default.